Effect of upadacitinib and ABBV-599 on biomarkers in SLE: results from the phase 2 SLEek study
4 affiliations
- 1Precision Medicine Immunology, AbbVie Inc, Chicago, Illinois, USA
- 2Quantitative Medicine and Genomics, AbbVie Inc, Chicago, Illinois, USA
- 3Data and Statistical Sciences, AbbVie Inc, Chicago, Illinois, USA
- 4Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
Abstract
Objective: Dual targeting of type I interferon and B-cell pathways could be a promising strategy for SLE. We examined biomarker and gene expression changes over 24 weeks in patients treated with upadacitinib, a Janus kinase (JAK) inhibitor that modulates interferon signalling, alone or in combination with elsubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor that targets B-cell pathways.
Methods: SLEek (NCT03978520), a phase 2, randomised, double-blind, placebo-controlled study, enrolled adults with moderately to severely active SLE. This analysis includes patients who received upadacitinib 30 mg (n=62), ABBV-599 (upadacitinib 30 mg plus elsubrutinib 60 mg; n=68) or placebo (n=75). Whole blood was collected at baseline (week 0) and various time points over 24 weeks to analyse serum immunoglobulins, immune cell counts and proteomic profiles. Weighted gene coexpression network analyses evaluated differentially expressed genes.
Results: Both upadacitinib and ABBV-599 significantly reduced and sustained lower anti-double-stranded DNA autoantibody levels compared with baseline through week 24, whereas upadacitinib monotherapy alone reduced plasma cell percentages. Proteomic analysis found modulation of 301 proteins, including reductions in interferon-related and B-cell-associated proteins. RNA sequencing revealed significant changes in interferon, plasma cells and cell cycle gene modules correlating with clinical biomarkers.
Conclusions: Upadacitinib was associated with a reduction in both autoantibody and B-cell activation and with key gene expression changes in SLE pathogenic pathways. Dual JAK/BTK inhibition did not provide additional impact on most immunological parameters. These findings support JAK inhibition as a targeted monotherapy for SLE.
Trial registration number: NCT03978520.
Related
- The α2‐Subunit Preferring GABA Positive Allosteric Modulator, N‐Desmethyl‐Clobazam in Peripheral Neuropathic Pain Patients: Results of a Phase IIa Randomised Placebo‐Controlled Ascending Dose Study
- UM171-Expanded Cord Blood Transplantation in Adults with High- and Very High-Risk Acute Leukemia and Myelodysplastic Syndrome: Combined Results of Two Prospective Phase II Trials
- CO112 | LIPOPROTEIN(a) PLASMA LEVELS AND COAGULATION BIOMARKERS: RESULTS FROM A COMPREHENSIVE LABORATORY ASSESSMENT IN AN ANGIOGRAPHICALLY-CONTROLLED CARDIOVASCULAR COHORT
- A Single Suprachoroidal Injection of AXT107 (Gersizangitide), a Multimodal, Long-Acting Integrin-Disrupting Peptide, in Patients with Neovascular Age-Related Macular Degeneration: Results of the Phase 1/2a DISCOVER Trial
- 535 BC3195, a novel cadherin-3 targeting antibody drug conjugate, combined with pembrolizumab in patients with advanced solid malignancies: preliminary results from a phase I/II study (BC3195-103/G36)
BibTeX
@article{gaudreau2026effect,
title = {{Effect of upadacitinib and ABBV-599 on biomarkers in SLE: results from the phase 2 SLEek study}},
author = {Marie-Claude Gaudreau and Michelle Catalina and Thierry Sornasse and Archana Iyer and Ioan Filip and Shalina Contrepois and James Fann and Joan T Merrill},
journal = {Lupus Science \& Medicine},
year = {2026},
month = oct,
doi = {10.1136/lupus-2026-002162},
url = {https://doi.org/10.1136/lupus-2026-002162},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Effect of upadacitinib and ABBV-599 on biomarkers in SLE: results from the phase 2 SLEek study
AU - Marie-Claude Gaudreau
AU - Michelle Catalina
AU - Thierry Sornasse
AU - Archana Iyer
AU - Ioan Filip
AU - Shalina Contrepois
AU - James Fann
AU - Joan T Merrill
PY - 2026
DA - 2026/10/29
JO - Lupus Science & Medicine
DO - 10.1136/lupus-2026-002162
UR - https://doi.org/10.1136/lupus-2026-002162
AB - Objective: Dual targeting of type I interferon and B-cell pathways could be a promising strategy for SLE. We examined biomarker and gene expression changes over 24 weeks in patients treated with upadacitinib, a Janus kinase (JAK) inhibitor that modulates interferon signalling, alone or in combination with elsubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor that targets B-cell pathways. Methods: SLEek (NCT03978520), a phase 2, randomised, double-blind, placebo-controlled study, enrolled adults with moderately to severely active SLE. This analysis includes patients who received upadacitinib 30 mg (n=62), ABBV-599 (upadacitinib 30 mg plus elsubrutinib 60 mg; n=68) or placebo (n=75). Whole blood was collected at baseline (week 0) and various time points over 24 weeks to analyse serum immunoglobulins, immune cell counts and proteomic profiles. Weighted gene coexpression network analyses evaluated differentially expressed genes. Results: Both upadacitinib and ABBV-599 significantly reduced and sustained lower anti-double-stranded DNA autoantibody levels compared with baseline through week 24, whereas upadacitinib monotherapy alone reduced plasma cell percentages. Proteomic analysis found modulation of 301 proteins, including reductions in interferon-related and B-cell-associated proteins. RNA sequencing revealed significant changes in interferon, plasma cells and cell cycle gene modules correlating with clinical biomarkers. Conclusions: Upadacitinib was associated with a reduction in both autoantibody and B-cell activation and with key gene expression changes in SLE pathogenic pathways. Dual JAK/BTK inhibition did not provide additional impact on most immunological parameters. These findings support JAK inhibition as a targeted monotherapy for SLE. Trial registration number: NCT03978520.
SN - 2053-8790
ER -